| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10962801 | Vaccine | 2016 | 11 Pages |
Abstract
Given current meningococcal epidemiology in France and the available data on the protection provided by Bexsero®, our modelling work showed that routine vaccination against serogroup B meningococcal disease is not cost-effective.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Héloïse Lecocq, Isabelle Parent du Châtelet, Muhamed-Kheir Taha, Daniel Lévy-Bruhl, Benoit Dervaux,